A Phase 4 interventional study of esomeprazole (Nexium®) and Xolaam® in GERD, sponsored by AstraZeneca. Completed at 1 site in France. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2012-12-11.
Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies testing esomeprazole in Gastroesophageal Reflux — 1 open to participants now, 1 under way, none of them phase 3. Esomeprazole · Gastroesophageal Reflux.
Among the 67 studies testing esomeprazole in Gastroesophageal Reflux, this one has the largest enrollment of the 66 interventional ones that give a count, is one of 3 that started in 2007, is one of 28 in phase 4, and was the 27th registered.
1,215 studies on the registry are indexed under Gastroesophageal Reflux; 204 are open to participants now.
Browse Gastroesophageal Reflux studies →1 of the 67 studies testing esomeprazole in Gastroesophageal Reflux is open now, in 1 country. Recruiting first, the newest first:
Asian Institute of Gastroenterology, India · Sites in India
Ages 18–75
By country, each count listing its studies:
Esomeprazole: first FDA approval 2001 (NEXIUM), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 134 Gastroesophageal Reflux studies recruiting now, 58 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 8 · Phase 3 17 · Phase 4 28
First in 2001; this study’s year is marked. 3 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3,029 is above the median of 68 across 800 interventional studies indexed under Gastroesophageal Reflux.
Median enrollment 125 across the 66 interventional studies. Of the 58 that completed or were terminated, 13 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
43 of 67 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
89 studies in Gastroesophageal Reflux by AstraZeneca: none open now, none under way, none of them phase 3. Of 89 finished, 15 (17%) have results posted.
Among the 89 studies in Gastroesophageal Reflux by AstraZeneca, this one has the largest enrollment of the 52 interventional ones that give a count, is one of 9 that started in 2007, is one of 21 in phase 4, and was the 25th registered.
AstraZeneca’s Gastroesophageal Reflux studies by the year they started, since 1998.
1 of the studies testing esomeprazole in Gastroesophageal Reflux that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06953986Asian Institute of Gastroenterology, IndiaA Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks | 2026-11-20 |
Add it to your calendar (.ics) → With an account.
Among the 67 studies testing esomeprazole in Gastroesophageal Reflux, from their registry updates:
Among AstraZeneca’s 89 in Gastroesophageal Reflux:
This tab as a report to print or save as PDF → With an account.
To compare the efficacy of three different long-term treatment strategies of reflux disease in primary care setting.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: esomeprazole (Nexium®)
Drug: esomeprazole (Nexium®)
Drug: esomeprazole (Nexium®)
Drug: esomeprazole (Nexium®)
Drug: Xolaam®
This randomized study was conducted on parallel groups and included two phases: * One initial phase during when the patients received once daily, either esomeprazole 20 mg or esomeprazole 40 mg, depending on the investigator's decision * One maintenance treatment phase, patients were randomized to one of the following three groups, either esomeprazole 20 mg once daily, or esomeprazole 20 mg on demand or antacid treatment as needed
This randomized study was conducted on parallel groups and included two phases: * One initial phase during when the patients received once daily, either esomeprazole 20 mg or esomeprazole 40 mg, depending on the investigator's decision * One maintenance treatment phase, patients were randomized to one of the following three groups, either esomeprazole 20 mg once daily, or esomeprazole 20 mg on demand or antacid treatment as needed
Efficacy of Three Strategies of Long-term Treatment
Percentage of failure of maintenance treatment between V2 (4 weeks) and V3 (16 weeks) evaluated by the patient, defined based on responses to 2 questions (if at least 1 negative response was given, the patient was considered to be in failure) : Did the treatment produce sufficient control of reflux symptoms? Do you wish to continue the treatment?
Time frame: 16 weeks
Difference in Symptom Severity Evaluation Performed by the Investigators, When Symptom Severity is Assessed With and Without Reflux Disease Questionnaire (RDQ).
Total percentage of subjects for whom evaluation of symptom severity using the Reflux Disease Questionnaire (RDQ) is different, either positively or negatively, as compared to clinical judgment made by Investigator. The RDQ Includes 12 Items: 6 Concern the Frequency of Symptoms Ranging From "Never" for the Lowest Frequency to "Every Day" for the Highest, 6 Others Assess the Severity of Symptoms From "Not at All" to "Strong". The Total Score of the RDQ, Ranging From 0 to 40, is Obtained by Adding the Scores of Each Item.
Time frame: 4 weeks
Impact of Treatment With Low Dose Aspirin (Acetyl Salicylic Acid) Used Concomitantly During the Initial Phase and the Maintenance Phase
No possibility to describe as only 2 patients took ASA
Time frame: 4 weeks
Differences Among Strategies of Maintenance Treatment for Satisfaction of the Patient, Using the GIS (Gord Impact Scale) Scale.(Change in Values of Score Derived From the GIS Questionnaire From V2 to V3 = Start to End of the Maintenance Phase)
Change in values of upper digestive symptoms (GORD Impact Scale) from week 4 to week 16. Scale of 1 to 4 : 1 = every day, 2 = often, 3 = sometime, 4 = never)
Time frame: 4 to 16 weeks
Impact of Anxiety and Depression During the Initial Visit Measured by the HADS ( Hospital Anxiety and Depression Scale) Questionnaire on Response to Initial Treatment and to Maintenance Treatment
Failure of treatment (as defined as in primary outcome measure) according to confirmed anxiety and depression during maintenance treatment evaluated by the patient via the score of HADS questionnaire. HADS scale ranges= 0 to 21 (the higher score, the worse : ≤7 : no anxiety-depression/ \[8-10\] : possible anxiety-depression/ \>10 : anxiety-depression)
Time frame: 16 weeks
Number of Participants and Type of Serious Adverse Events and Adverse Events Leading to a Premature Discontinuation of the Study
Number of participants with serious adverse events and adverse events leading to study treatment discontinuation. AE and SAE as defined in ICH-GCP.
Time frame: 12 weeks - maintenance treatment phase
Score Abacuses Based on the Reflux Disease Questionnaire (RDQ) Questionnaire
May be used to evaluate the severity of symptoms during the initial visit. Not done
Time frame: Day 0
Score Abacuses Based on the Reflux Disease Questionnaire (RDQ) Questionnaire
May be used to offer patients a strategy of treatment during the initial phase and in the long term. Not done
Time frame: Day 0
Score Abacuses Based on the Reflux Disease Questionnaire (RDQ)
May be used to define the success of treatment. Not done
Time frame: Week 4
Patients were recruited by general practitioner between March 1, 2007 and July 21, 2008
| Milestone | Esomeprazole 20 mg Once Daily (Initial Phase) | Esomeprazole 40 mg Once Daily (Initial Phase) | Esomeprazole 20 mg Once Daily (Maintenance Phase) | Esomeprazole 20 mg on Demand (Maintenance Phase) | Antacid Treatment (Maintenance Phase) |
|---|---|---|---|---|---|
| Started | 2156 | 873 | 0 | 0 | 0 |
| Completed | 1908 | 777 | 0 | 0 | 0 |
| Not completed | 248 | 96 | 0 | 0 | 0 |
| Milestone | Esomeprazole 20 mg Once Daily (Initial Phase) | Esomeprazole 40 mg Once Daily (Initial Phase) | Esomeprazole 20 mg Once Daily (Maintenance Phase) | Esomeprazole 20 mg on Demand (Maintenance Phase) | Antacid Treatment (Maintenance Phase) |
|---|---|---|---|---|---|
| Started | 0 | 0 | 908 | 897 | 880 |
| Completed | 0 | 0 | 747 | 764 | 701 |
| Not completed | 0 | 0 | 161 | 133 | 179 |
| Withdrew: Didn'r receive the treatment | 0 | 0 | 22 | 17 | 29 |
| Withdrew: Lost to follow-up | 0 | 0 | 8 | 14 | 10 |
| Withdrew: Adverse event | 0 | 0 | 3 | 2 | 13 |
| Withdrew: Protocol specific criteria's development | 0 | 0 | 1 | 0 | 6 |
| Withdrew: Patient's wish | 0 | 0 | 19 | 9 | 20 |
| Withdrew: Protocol violation | 0 | 0 | 103 | 88 | 87 |
| Withdrew: Ineffectiveness | 0 | 0 | 5 | 3 | 14 |
Percentage of failure of maintenance treatment between V2 (4 weeks) and V3 (16 weeks) evaluated by the patient, defined based on responses to 2 questions (if at least 1 negative response was given, the patient was considered to be in failure) : Did the treatment produce sufficient control of reflux symptoms? Do you wish to continue the treatment?
| Percentage of participants with failure | Esomeprazole 20 mg Once Daily (Maintenance Phase) | Esomeprazole 20 mg on Demand (Maintenance Phase) | Antacid Treatment (Maintenance Phase) |
|---|---|---|---|
| Efficacy of Three Strategies of Long-term Treatment | 10.6 | 7.8 | 43 |
Total percentage of subjects for whom evaluation of symptom severity using the Reflux Disease Questionnaire (RDQ) is different, either positively or negatively, as compared to clinical judgment made by Investigator. The RDQ Includes 12 Items: 6 Concern the Frequency of Symptoms Ranging From "Never" for the Lowest Frequency to "Every Day" for the Highest, 6 Others Assess the Severity of Symptoms From "Not at All" to "Strong". The Total Score of the RDQ, Ranging From 0 to 40, is Obtained by Adding the Scores of Each Item.
| Percentage of participants | Esomeprazole 20 mg Once Daily (Initial Phase) | Esomeprazole 40 mg Once Daily (Initial Phase) | Esomeprazole 20 mg Once Daily (Maintenance Phase) | Esomeprazole 20 mg on Demand (Maintenance Phase) | Antacid Treatment (Maintenance Phase) |
|---|---|---|---|---|---|
| Difference in Symptom Severity Evaluation Performed by the Investigators, When Symptom Severity is Assessed With and Without Reflux Disease Questionnaire (RDQ). | 3.7 | 2.3 | — | — | — |
No possibility to describe as only 2 patients took ASA
No measurements were reported for this outcome.
Change in values of upper digestive symptoms (GORD Impact Scale) from week 4 to week 16. Scale of 1 to 4 : 1 = every day, 2 = often, 3 = sometime, 4 = never)
| Scores on scale | Esomeprazole 20 mg Once Daily (Initial Phase) | Esomeprazole 40 mg Once Daily (Initial Phase) | Esomeprazole 20 mg Once Daily (Maintenance Phase) | Esomeprazole 20 mg on Demand (Maintenance Phase) | Antacid Treatment (Maintenance Phase) |
|---|---|---|---|---|---|
| Differences Among Strategies of Maintenance Treatment for Satisfaction of the Patient, Using the GIS (Gord Impact Scale) Scale.(Change in Values of Score Derived From the GIS Questionnaire From V2 to V3 = Start to End of the Maintenance Phase) | — | — | 0.12 ± 0.79 | 0.04 ± 0.73 | -0.22 ± 0.8 |
Failure of treatment (as defined as in primary outcome measure) according to confirmed anxiety and depression during maintenance treatment evaluated by the patient via the score of HADS questionnaire. HADS scale ranges= 0 to 21 (the higher score, the worse : ≤7 : no anxiety-depression/ \[8-10\] : possible anxiety-depression/ \>10 : anxiety-depression)
| Percent of participants with failure | Esomeprazole 20 mg Once Daily (Initial Phase) | Esomeprazole 40 mg Once Daily (Initial Phase) | Esomeprazole 20 mg Once Daily (Maintenance Phase) | Esomeprazole 20 mg on Demand (Maintenance Phase) | Antacid Treatment (Maintenance Phase) |
|---|---|---|---|---|---|
| Impact of Anxiety and Depression During the Initial Visit Measured by the HADS ( Hospital Anxiety and Depression Scale) Questionnaire on Response to Initial Treatment and to Maintenance Treatment | — | — | 9.8 | 9.3 | 43.7 |
Number of participants with serious adverse events and adverse events leading to study treatment discontinuation. AE and SAE as defined in ICH-GCP.
| Participants | Esomeprazole 20 mg Once Daily (Initial Phase) | Esomeprazole 40 mg Once Daily (Initial Phase) | Esomeprazole 20 mg Once Daily (Maintenance Phase) | Esomeprazole 20 mg on Demand (Maintenance Phase) | Antacid Treatment (Maintenance Phase) |
|---|---|---|---|---|---|
| Number of Participants and Type of Serious Adverse Events and Adverse Events Leading to a Premature Discontinuation of the Study | — | — | 5 | 4 | 15 |
May be used to evaluate the severity of symptoms during the initial visit. Not done
No measurements were reported for this outcome.
May be used to offer patients a strategy of treatment during the initial phase and in the long term. Not done
No measurements were reported for this outcome.
May be used to define the success of treatment. Not done
No measurements were reported for this outcome.
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Esomeprazole 20 mg Once Daily (Initial Phase) | — | 8/2,156 (0.4%) | 32/2,156 (1.5%) |
| Esomeprazole 40 mg Once Daily (Initial Phase) | — | 2/873 (0.2%) | 16/873 (1.8%) |
| Esomeprazole 20 mg Once Daily (Maintenance Phase) | — | 2/886 (0.2%) | 5/886 (0.6%) |
| Esomeprazole 20 mg on Demand (Maintenance Phase) | — | 3/880 (0.3%) | 2/880 (0.2%) |
| Antacid Treatment (Maintenance Phase) | — | 4/851 (0.5%) | 13/851 (1.5%) |
| Event | Esomeprazole 20 mg Once Daily (Initial Phase) | Esomeprazole 40 mg Once Daily (Initial Phase) | Esomeprazole 20 mg Once Daily (Maintenance Phase) | Esomeprazole 20 mg on Demand (Maintenance Phase) | Antacid Treatment (Maintenance Phase) |
|---|---|---|---|---|---|
| AGGRAVATION OF INTERVERTEBRAL DISC HERNIATIONMusculoskeletal and connective tissue disorders | 0/2156 | 0/873 | 0/886 | 0/880 | 1/851 |
| RENAL COLICRenal and urinary disorders | 0/2156 | 0/873 | 0/886 | 0/880 | 1/851 |
| ADENOCARCINOM A OF GASTRIC ANTRUMNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/2156 | 0/873 | 0/886 | 0/880 | 1/851 |
| METRORRHAGIAReproductive system and breast disorders | 0/2156 | 0/873 | 0/886 | 0/880 | 1/851 |
| EROSIVE ANTRITISGastrointestinal disorders | 0/2156 | 1/873 | 0/886 | 0/880 | 0/851 |
| PNEUMOPATHYRespiratory, thoracic and mediastinal disorders | 0/2156 | 1/873 | 0/886 | 0/880 | 0/851 |
| GASTRIC ULCERGastrointestinal disorders | 0/2156 | 0/873 | 0/886 | 1/880 | 0/851 |
| DEPRESSIONPsychiatric disorders | 0/2156 | 0/873 | 0/886 | 1/880 | 0/851 |
| DIGESTIVE VIROSISInfections and infestations | 0/2156 | 0/873 | 0/886 | 1/880 | 0/851 |
| SPONDYLOLISTHE SIS AGGRAVATION BY L5 SPONDYLOLYSISMusculoskeletal and connective tissue disorders | 0/2156 | 0/873 | 1/886 | 0/880 | 0/851 |
| Event | Esomeprazole 20 mg Once Daily (Initial Phase) | Esomeprazole 40 mg Once Daily (Initial Phase) | Esomeprazole 20 mg Once Daily (Maintenance Phase) | Esomeprazole 20 mg on Demand (Maintenance Phase) | Antacid Treatment (Maintenance Phase) |
|---|---|---|---|---|---|
| DyspepsiaVascular disorders | 2/2156 | 2/873 | 1/886 | 1/880 | 3/851 |
| Abdominal pain upperGastrointestinal disorders | 0/2156 | 1/873 | 0/886 | 0/880 | 2/851 |
| Gastrointestinal disorderGastrointestinal disorders | 0/2156 | 0/873 | 0/886 | 0/880 | 2/851 |
| HeadacheNervous system disorders | 5/2156 | 2/873 | 1/886 | 0/880 | 0/851 |
| AstheniaGeneral disorders | 0/2156 | 2/873 | 0/886 | 0/880 | 0/851 |
| Abdominal painGastrointestinal disorders | 4/2156 | 0/873 | 0/886 | 0/880 | 0/851 |
| NauseaGastrointestinal disorders | 4/2156 | 1/873 | 0/886 | 0/880 | 1/851 |
| DiarrheaGastrointestinal disorders | 3/2156 | 0/873 | 0/886 | 0/880 | 1/851 |
| VertigoEar and labyrinth disorders | 3/2156 | 1/873 | 1/886 | 0/880 | 0/851 |
| Gastroesophageal reflux diseaseGastrointestinal disorders | 0/2156 | 0/873 | 0/886 | 0/880 | 1/851 |
| Age Continuous(years) | Esomeprazole 20 mg Once Daily (Maintenance Phase) | Esomeprazole 20 mg on Demand (Maintenance Phase) | Antacid Treatment (Maintenance Phase) | Total |
|---|---|---|---|---|
| Mean | 41.5 ± 9.83 | 41.79 ± 9.97 | 41.6 ± 10 | 41.64 ± 9.91 |
| Sex: Female, Male(Participants) | Esomeprazole 20 mg Once Daily (Maintenance Phase) | Esomeprazole 20 mg on Demand (Maintenance Phase) | Antacid Treatment (Maintenance Phase) | Total |
|---|---|---|---|---|
| Female | 449 | 415 | 411 | 1275 |
| Male | 422 | 442 | 419 | 1283 |
The record gives a start of Mar 2007, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2012, 4 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Esomeprazole